Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pearce

Showing results (401-410 of 419) with videos related to

Pageof 42
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivoKuo-Long Yu, Xiangdong Alan Wang, Rita L Civiello, et al.
BMC Microbiology|December 31, 2009
Temporal and spatial patterns of bovine Escherichia coli O157 prevalence and comparison of temporal changes in the patterns of phage types associated with bovine shedding and human E. coli O157 cases in Scotland between 1998-2000 and 2002-2004Michael C Pearce, Margo E Chase-Topping, Iain J McKendrick, et al.
ACS Medicinal Chemistry Letters|March 18, 2021
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1Andrew P Degnan, Godwin K Kumi, Christopher W Allard, et al.
Bioorganic & Medicinal Chemistry Letters|July 10, 2007
Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moietyKeith D Combrink, H Belgin Gulgeze, Jan W Thuring, et al.
Nature Communications|November 13, 2023
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse modelTracy-Shi Zhang Fang, Yu Sun, Andrew C Pearce, et al.
Bioorganic & Medicinal Chemistry|December 5, 2016
Triazolopyridine ethers as potent, orally active mGlu<sub>2</sub> positive allosteric modulators for treating schizophreniaMendi A Higgins, Lawrence R Marcin, F Christopher Zusi, et al.
Journal of Medicinal Chemistry|August 10, 2016
Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial HypertensionDuncan E Shaw, Ferheen Baig, Ian Bruce, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
Neurobiology of Aging|September 21, 2021
Lifestyle and the aging brain: interactive effects of modifiable lifestyle behaviors and cognitive ability in men from midlife to old ageCarol E Franz, Sean N Hatton, Jeremy A Elman, et al.
The Journal of Biological Chemistry|July 18, 2021
GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in miceAndrew C Pearce, Mark J Bamford, Ruth Barber, et al.
Pageof 42

Showing results (401-410 of 419) with videos related to

Sort By:
Pageof 42
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivoKuo-Long Yu, Xiangdong Alan Wang, Rita L Civiello, et al.
BMC Microbiology|December 31, 2009
Temporal and spatial patterns of bovine Escherichia coli O157 prevalence and comparison of temporal changes in the patterns of phage types associated with bovine shedding and human E. coli O157 cases in Scotland between 1998-2000 and 2002-2004Michael C Pearce, Margo E Chase-Topping, Iain J McKendrick, et al.
ACS Medicinal Chemistry Letters|March 18, 2021
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1Andrew P Degnan, Godwin K Kumi, Christopher W Allard, et al.
Bioorganic & Medicinal Chemistry Letters|July 10, 2007
Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moietyKeith D Combrink, H Belgin Gulgeze, Jan W Thuring, et al.
Nature Communications|November 13, 2023
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse modelTracy-Shi Zhang Fang, Yu Sun, Andrew C Pearce, et al.
Bioorganic & Medicinal Chemistry|December 5, 2016
Triazolopyridine ethers as potent, orally active mGlu<sub>2</sub> positive allosteric modulators for treating schizophreniaMendi A Higgins, Lawrence R Marcin, F Christopher Zusi, et al.
Journal of Medicinal Chemistry|August 10, 2016
Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial HypertensionDuncan E Shaw, Ferheen Baig, Ian Bruce, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
Neurobiology of Aging|September 21, 2021
Lifestyle and the aging brain: interactive effects of modifiable lifestyle behaviors and cognitive ability in men from midlife to old ageCarol E Franz, Sean N Hatton, Jeremy A Elman, et al.
The Journal of Biological Chemistry|July 18, 2021
GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in miceAndrew C Pearce, Mark J Bamford, Ruth Barber, et al.
Pageof 42